Loading...

Mina Nikanjam

Title(s)Assistant Clinical Professor, Medicine
SchoolHealth Sciences
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Poddar S, Capparelli EV, Rosser EW, Gipson RM, Wei L, Le T, Jung ME, Radu C, Nikanjam M. Development and preclinical pharmacology of a novel dCK inhibitor, DI-87. Biochem Pharmacol. 2019 Dec 06; 172:113742. PMID: 31812677.
      View in: PubMed
    2. Nikanjam M, Okamura R, Barkauskas DA, Kurzrock R. Targeting fusions for improved outcomes in oncology treatment. Cancer. 2019 Dec 03. PMID: 31794076.
      View in: PubMed
    3. Kawakatsu S, Nikanjam M, Lin M, Le S, Saunders I, Kuo DJ, Capparelli EV. Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients. Cancer Chemother Pharmacol. 2019 Dec; 84(6):1339-1348. PMID: 31586225.
      View in: PubMed
    4. Nikanjam M, Cohen PR, Kato S, Sicklick JK, Kurzrock R. Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics. Ann Oncol. 2019 Oct 01; 30(10):1675. PMID: 31408092.
      View in: PubMed
    5. Nikanjam M, Yang J, Capparelli EV. Population pharmacokinetics of siltuximab: impact of disease state. Cancer Chemother Pharmacol. 2019 Nov; 84(5):993-1001. PMID: 31482226.
      View in: PubMed
    6. Nikanjam M, Arguello D, Gatalica Z, Swensen J, Barkauskas DA, Kurzrock R. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients. Int J Cancer. 2019 Sep 03. PMID: 31479512.
      View in: PubMed
    7. Yang J, Nikanjam M, Capparelli EV, Tsunoda SM, Greenberg HE, Penzak SR, Stoch SA, Bertino JS, Nafziger AN, Ma JD. Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults. J Clin Pharmacol. 2019 Nov; 59(11):1495-1504. PMID: 31051051.
      View in: PubMed
    8. Lin S, Nikanjam M, Capparelli EV, Allegrini A, Pavone D, Yim DS, Hammami MM, Bertino JS, Nafziger AN, Park YS, Kang JS, Yin OQ, Ma JD. Evaluation of Omeprazole Limited Sampling Strategies to Estimate Constitutive Cytochrome P450 2C19 Activity in Healthy Adults. Ther Drug Monit. 2018 12; 40(6):754-758. PMID: 30045358.
      View in: PubMed
    9. Nikanjam M, Wing J, Capparelli E, Kurzrock R. Dosing Oncology Therapeutics in Combination Therapy for Renal Dysfunction: The University of California San Diego Study of Personalized Cancer Therapy to Determine Response and Toxicity (UCSD-PREDICT) Experience. Cureus. 2018 Nov 26; 10(11):e3634. PMID: 30705793.
      View in: PubMed
    10. Nikanjam M, Cohen PR, Kato S, Sicklick JK, Kurzrock R. Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics. Ann Oncol. 2018 11 01; 29(11):2192-2199. PMID: 30219896.
      View in: PubMed
    11. Yang J, Nikanjam M, Best BM, Pinto J, Chadwick EG, Daar ES, Havens PL, Rakhmanina N, Capparelli EV. Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood. J Clin Pharmacol. 2018 12; 58(12):1604-1617. PMID: 30252146.
      View in: PubMed
    12. Nikanjam M, Sun A, Albers M, Mangalindin K, Song E, Vempaty H, Sam D, Capparelli EV. Vincristine-associated Neuropathy With Antifungal Usage: A Kaiser Northern California Experience. J Pediatr Hematol Oncol. 2018 07; 40(5):e273-e277. PMID: 29771861.
      View in: PubMed
    13. Yang J, Patel M, Nikanjam M, Capparelli EV, Tsunoda SM, Greenberg HE, Penzak SR, Aubrey Stoch S, Bertino JS, Nafziger AN, Ma JD. Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach. J Clin Pharmacol. 2018 09; 58(9):1205-1213. PMID: 29663428.
      View in: PubMed
    14. Nikanjam M, Capparelli EV, Lancet JE, Louie A, Schiller G. Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment. Cancer Chemother Pharmacol. 2018 01; 81(1):171-178. PMID: 29167924.
      View in: PubMed
    15. Le TM, Poddar S, Capri JR, Abt ER, Kim W, Wei L, Uong NT, Cheng CM, Braas D, Nikanjam M, Rix P, Merkurjev D, Zaretsky J, Kornblum HI, Ribas A, Herschman HR, Whitelegge J, Faull KF, Donahue TR, Czernin J, Radu CG. ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways. Nat Commun. 2017 08 14; 8(1):241. PMID: 28808226.
      View in: PubMed
    16. Nikanjam M, Patel H, Kurzrock R. Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns. Oncoimmunology. 2017; 6(8):e1338997. PMID: 28920006.
      View in: PubMed
    17. Nikanjam M, Liu S, Yang J, Kurzrock R. Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients. Oncologist. 2017 05; 22(5):576-584. PMID: 28424323.
      View in: PubMed
    18. Nikanjam M, Liu S, Kurzrock R. Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013. Int J Cancer. 2016 Nov 01; 139(9):2135-41. PMID: 27389805.
      View in: PubMed
    19. Liu S, Nikanjam M, Kurzrock R. Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers. Oncotarget. 2016 Mar 08; 7(10):11310-20. PMID: 26824502.
      View in: PubMed
    20. Nikanjam M, Stewart CF, Takimoto CH, Synold TW, Beaty O, Fouladi M, Capparelli EV. Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing. Cancer Chemother Pharmacol. 2015 Mar; 75(3):495-503. PMID: 25557868.
      View in: PubMed
    21. Nikanjam M, Kabamba D, Cressey TR, Burger D, Aweeka FT, Acosta EP, Spector SA, Capparelli EV. Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience. Antimicrob Agents Chemother. 2012 Oct; 56(10):5374-80. PMID: 22869579.
      View in: PubMed
    22. Nikanjam M, Chadwick EG, Robbins B, Alvero C, Palumbo P, Yogev R, Pinto J, Hazra R, Hughes ML, Heckman BE, Capparelli EV. Assessment of lopinavir pharmacokinetics with respect to developmental changes in infants and the impact on weight band-based dosing. Clin Pharmacol Ther. 2012 Feb; 91(2):243-9. PMID: 22190064.
      View in: PubMed
    23. Tremoulet AH, Nikanjam M, Cressey TR, Chokephaibulkit K, McKinney R, Mirochnick M, Capparelli EV. Developmental pharmacokinetic changes of Lamivudine in infants and children. J Clin Pharmacol. 2012 Dec; 52(12):1824-32. PMID: 22180560.
      View in: PubMed
    24. Sleasman JW, Robbins BL, Cross SJ, Lindsey JC, Kraimer JM, Heckman BE, Sprenger HL, Tustin NB, Rose CH, Poston PA, Neal EF, Pakes GE, Nikanjam M, Capparelli EV. Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults. Clin Pharmacol Ther. 2009 Apr; 85(4):394-401. PMID: 19118380.
      View in: PubMed
    25. Nikanjam M, Gibbs AR, Hunt CA, Budinger TF, Forte TM. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J Control Release. 2007 Dec 20; 124(3):163-71. PMID: 17964677.
      View in: PubMed
    26. Nikanjam M, Kursa K, Lehman S, Lattanza L, Diao E, Rempel D. Finger flexor motor control patterns during active flexion: an in vivo tendon force study. Hum Mov Sci. 2007 Feb; 26(1):1-10. PMID: 17173995.
      View in: PubMed
    27. Nikanjam M, Blakely EA, Bjornstad KA, Shu X, Budinger TF, Forte TM. Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. Int J Pharm. 2007 Jan 02; 328(1):86-94. PMID: 16959446.
      View in: PubMed
    Mina's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (117) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (20) people
    _
    Similar People
    People who share similar concepts with this person.
    See all (60) people
    _
    Same Department
    Search Department
    ↑